ArticleBioprocess and biosystems engineering2026
Improvement of protein purity in etanercept production through process optimization in recombinant CHO cell-based transient gene expression system.
Article in Bioprocess and biosystems engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maintaining high protein purity is crucial for ensuring the efficacy, safety, and productivity of therapeutic glycoproteins. Given that proteins produced within transient gene expression (TGE) systems are ultimately intended for incorporation into production cell lines developed using stable gene expression (SGE) systems, it is crucial to evaluate protein purity across both systems and explore strategies for improvement. In this study, elevated levels of both high- and low-molecular-weight impurities were observed in etanercept (ETN) produced under the evaluated TGE conditions compared with the SGE system. To address these purity concerns, we investigated the effects of various process modifications, including chemical treatments, temperature downshifts, and adjustments to kit components within the TGE system. Results indicated that rapamycin treatment, a temperature downshift to 30 °C, and the omission of Enhancer material increased the monomer proportion of ETN. Combining a temperature downshift to 30 °C with omission of the Enhancer material reduced overall ETN production but increased the monomer ratio to levels comparable to those in the SGE system. Moreover, the combination of rapamycin treatment, a temperature downshift to 30 °C, and an extended culture duration significantly enhanced both total and monomer ETN production while maintaining higher purity. These improvements were similarly observed in the HEK293 cell-based TGE system, demonstrating that the optimized culture conditions possess broad applicability across mammalian TGE systems. These findings demonstrate that comprehensive optimization of culture parameters can significantly enhance protein purity in TGE-based protein production, enabling purity levels comparable to those obtained from SGE systems under the conditions evaluated in this study.
Indexed as
Identifiers
41801332What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.